Webinar – Faster to Market: Transforming HEOR & RWE Using Virtual Sourcing
Wish you could get HEOR & RWE projects started faster, cheaper, & using the most optimal vendor? Do you want [...]
Predictions for RWE in 2020
A recent article published on PharmaTimes looks at what the future may hold for real-world evidence amid rising interest in [...]
RWE 2020 Postponed Until Later This Year
The Real-World Evidence 2020: Rare Diseases and Innovative Therapies event has been postponed to later this year in response to [...]
Opinion: Hub Providers Can Provide ‘Best’ RWE
The pharmaceutical industry's hub and patient-support providers could be the source of the "best" real-world evidence, the author of a [...]
NPC’s Leonard Outlines Findings of Research on Coverage Decisions
National Pharmaceutical Council President and CEO Dan Leonard in a recent write up published on Pharmacy Times outlines some key [...]
Tackling Rare Diseases with an Arsenal of Real-World Data
Technological innovations have fostered the age of big data in healthcare – and the huge populations amassed afford the ability to mine for key subpopulations -- getting down to ever more precise groups of likely responders to therapy, high-risk patients and other high-value subphenotypes.
Social Determinants of Health: When Health Care is More Than Just Medicine
CMS projects that national health spending in the United States (US) will reach almost $6 trillion by 2027. Can a focus on social risk improve health and moderate skyrocketing costs?
ICER Announces RWE Partnership with Aetion
The Institute for Clinical and Economic Review (ICER) is partnering with Aetion to "generate decision-grade real-world evidence," the drug pricing [...]
COTA White Paper Spotlights Perspectives on RWE
A new white paper from COTA offers unique perspectives on real-world evidence (RWE), including input from Pfizer and Bristol-Myers Squibb [...]
Randomization vs. Real-World Evidence
Nonrandomized observational studies have been touted by some as being a viable alternative to randomized clinical trials, but are they [...]
New RWE Company Partnering with Medical Societies for Data
A new real-world evidence company, Verana Health, is partnering with medical societies to obtain data for research in eye disease [...]
NICE Looks to Include EHRs, RWE in Guidance
The U.K.'s National Institute for Health and Care Excellence (NICE) announced plans to incorporate electronic health records and real-world evidence [...]
Report: ICER to Assess RWE on Accelerated Approvals
The Institute for Clinical and Economic Review (ICER) will incorporate real-world evidence into future updates of already-reviewed according to a [...]
Optimizing Real-World Evidence in Medical Device Development
The use of real-world data to generate RWE for medical devices by industry has become more prominent in recent years, and more attractive to a variety of stakeholders. It is used frequently to understand the use of the device in the larger clinical setting, but more recently it is also being used for regulatory decision making.
Survey Finds Increasing Interest in Patient-Reported Data from Outcomes-Based Contracts
A new survey conducted by Avalere Health suggests rising interest among payers to generate patient-reported data through outcomes-based contracts, according [...]
Page Talks Patient-Centered Pathways, RWE, AI
Center for Cancer and Blood Disorders President and Director of Research Ray Page in a recent podcast posted on the [...]
Article Reflects on FDA’s Moves in Last Decade
A recent article by The Pink Sheet takes a step back to highlight how the Food and Drug Administration (FDA) [...]
Report Spotlights RWE in Medical Affairs
A recent report by FirstWord Pharma looks at how real-world evidence is performing in the medical affairs landscape. The report [...]
ISPOR Publishes Report Top 10 HEOR Trends
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) this week published its 2020 Top 10 HEOR Trends report. "As [...]
Article Highlights CanREValue Collaboration for RWE
A recent article published in BMJ highlights efforts by the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, [...]
How Artificial Intelligence and Real World Data Can Improve the Management of Type 2 Diabetes: A Case Study
See how Veradigm, a business unit of Allscripts focused on generating data-driven healthcare insights using EHR data applied artificial intelligence to EHRs to improve therapeutic management of patients with concordant comorbidities who are living with type 2 diabetes.
Using Innovative Data Analytics for Market Access
Dr. Patti Peeples, CEO of HealthEconomics.com, sat down with Walter Bouwmeester, Real-World Evidence and Data Analytics Lead in Europe, to discuss the use of data analytics to support multidimensional health economics and outcomes research (HEOR) in Europe.
Closing Gaps in Real-World Evidence through Data Linkage
Interview with Dr. Kevin Haynes, Principal Scientist, HealthCore-NERI. Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Kevin Haynes, [...]
Storytelling, Giving Back, and Legacy: How AESARA is Doing it Differently
A market access agency. https://aesara.com A few months ago, I was sipping my morning coffee and perusing the health economics [...]
Changing the Clinical Trial Paradigm for Rare and Orphan (R&O) Diseases using Real-World Evidence
Interview with Flora Sandra Siami, MPH. Vice President of Clinical Research, Regulatory Affairs, and Quality Assurance at HealthCore-NERI. Dr. Patti [...]